Anne-Lise Strandmoe, Jeroen Bremer, Gilles F H Diercks, Antoni Gostyński, Emanuele Ammatuna, Hendri H Pas, Marjan Wouthuyzen-Bakker, Gerwin A Huls, Peter Heeringa, Jon D Laman, Barbara Horváth
Pemphigus vulgaris is a rare autoimmune bullous disease characterized by blistering of the skin and mucosa owing to the presence of autoantibodies against the desmosome proteins desmoglein 3 and occasionally in conjunction with desmoglein 1. Fundamental research into the pathogenesis of PV has revolutionized its treatment and outcome with rituximab, a B-cell-depleting therapy. The critical contribution of B cells to the pathogenesis of pemphigus is well accepted. However, the exact pathomechanism, mechanisms of onset, disease course, and relapse remain unclear...
March 20, 2024: British Journal of Dermatology